



## **BIOSENSORS ANNOUNCES EUROPEAN PATENT GRANT COVERING DRUG TECHNOLOGY DEVELOPED IN-HOUSE**

*European patent grant is in addition to a US patent grant received earlier  
this year from the United States Patent and Trademark Office*

**Singapore, 13 August 2007** – Biosensors International Group, Ltd. (“Biosensors”, “Company”, Bloomberg: BIG SP), announced today that the European Patent Office has granted Biosensors a patent covering the manufacture, importation, sale, and use of the Company’s proprietary anti-restenosis drug, Biolimus A9™. The grant of this patent in Europe, combined with a similar grant in May of this year from the US Patent and Trademark Office, provides Biosensors with key intellectual property rights with respect to Biolimus A9 in European patent-treaty countries, Asia, the United States and elsewhere.

This newly-awarded European patent (Patent Number 1683754) includes 32 claims based on the use of Biolimus A9 in a number of important medical treatments including its application on polymer-coated stents, polymer-free stents, and through varied formulations, including pills, topical ointments, injectables, microbeads, tablets and others for the treatment of restenosis, wounds, vascular injury, inflammatory conditions as well as the prevention of “transplant rejection” in organ transplants.

John Shulze, Chief Technology Officer said, "Biolimus A9 is an important new pharmaceutical discovery because of its unique property of higher affinity to lipids compared to other available drugs used to coat drug-eluting stents. The special pharmacokinetic properties of Biolimus allow it to be more readily absorbed by cells, causing a more effective localized treatment and less systemic exposures to the body in areas outside of the stent. Biolimus A9 is incorporated in our BioMatrix™ drug-eluting stent that has demonstrated effectiveness in clinical trials with highly positive results and good safety profile. We believe that BioMatrix truly represents a good second-generation drug-eluting stent design with a biodegradable polymer coating that is believed to represent a major improvement over current generation drug-eluting stent designs.

“The grant of this European patent further confirms and strengthens our intellectual property portfolio particularly in the domain of drug-eluting stents and in other types of treatments for vascular disease which employ an active pharmaceutical agent. Beyond the use with drug eluting stents, the US and European patents granted for Biolimus A9 also extend the possibilities for alternative uses and applications of Biolimus A9 as a stand-alone drug therapy for potential applications ranging from dermatology, ophthalmic inflammation and wound healing, among others. The market potential in these opportunities can be very large.” Mr Shulze added.

### End of release ###

### **Media & Investor Relations**

#### **Singapore**

Mr. Loh Chee Mun  
Senior Vice President  
Tel: (65) 62135708  
Email: [cm.loh@biosensors.com](mailto:cm.loh@biosensors.com)

#### **United States**

##### ***Allen&Caron Inc.***

Mr. Matt Clawson  
Executive Vice President, Investor Relations  
Tel: (1) 949 474 4300  
Email: [matt@allencaron.com](mailto:matt@allencaron.com)

### **About Biosensors International Group, Ltd**

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional therapies such as bare-metal stenting and open-heart surgery. Biosensors has internally developed technology to address each component of a drug-eluting stent system, including a stent, a stent delivery catheter, a biodegradable polymer and a proprietary anti-restenosis drug. It is pursuing three separate drug-eluting stent programs, BioMatrix®, Axxion™, and BioMatrix® Freedom™, a polymer-free drug-eluting stent, and has licensed aspects of its drug eluting stent technology to four companies.

### **Forward Looking Statements**

*Certain statements herein include forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward looking statements generally can be identified by the use of forward looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward looking statements. The forward looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.*